NNVC: Tiny ticker. Huge potential. From measles to MPox — this
biotech could be 2026’s defining story. ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏
_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Equiscreen._
-------------------------
NANOVIRICIDES (NNVC) [[link removed]] NEARS CRITICAL
INFLECTION POINT WITH NV-387 PHASE 2 TRIALS THAT COULD LEAD TO
MULTI-BILLION-DOLLAR POTENTIAL AS ZACKS SMALL CAP RESEARCH ISSUES $7
VALUATION!
[biotech] [[link removed]]
NANOVIRICIDES (NYSE: NNVC) [[link removed]] is turning
heads in the biotech world as the company is advancing its lead drug
candidate NV-387 into PHASE 2 TRIALS FOR MPOX, targeting the most
recent outbreaks and potential U.S. biodefense applications.
Leveraging its NANOMEDICINE PLATFORM, NV-387 has demonstrated broad
antiviral activity in preclinical models against measles, influenza,
RSV, and orthopoxviruses.
With orphan drug designation applications in progress and dual-track
trials planned, NNVC is strategically positioned to capture multiple
markets while delivering A FIRST-OF-ITS-KIND BROAD-SPECTRUM ANTIVIRAL
THERAPY!
According to ZACKS SMALL CAP RESEARCH, the combination of
NV-387’s SAFETY RECORD, PROVEN EFFICACY IN ANIMAL MODELS, AND
REGULATORY STRATEGY offers a compelling investment case.
ZACKS HIGHLIGHTS THE UPSIDE POTENTIAL FROM GOVERNMENT STOCKPILE
PROCUREMENT, ORPHAN DRUG INCENTIVES, AND BARDA FUNDING, WHICH COULD
PROVIDE NON-DILUTIVE CAPITAL AND ACCELERATE COMMERCIAL ADOPTION.
With these catalysts on the horizon, NV-387 could become an essential
therapy for viral threats worldwide and could make NNVC a breakout
story in the biotech space next year.
LEARN WHY NNVC IS ON THE VERGE OF REDEFINING THE ANTIVIRAL MARKET
[[link removed]]
We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of NanoViricides, Inc. (NYSE American: NNVC). The compensation
consists of up to $6,500 and was received/will be received from
Interactive Offers.
This communication should not be considered as an endorsement of the
securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we
are not responsible for any errors or omissions in any information
provided about the securities of NanoViricides, Inc. (NYSE American:
NNVC) and Interactive Offers.
We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.
This disclosure is made as of 01/12/2026.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]
Behind the Markets
[[link removed]]
_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._
TODAY'S BONUS CONTENT: Top 10 AI Stocks to Buy In January
[[link removed]]
_(By clicking this link you agree to receive emails from Trading
Tips and our affiliates. You can opt out at any time. -__ __Privacy
Policy)_ [[link removed]]
